Pinkas Lebovits, MD
Dermatology · New York, NYNPI 1023015245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 32.8% of the total. Reporting peaked in 2022 at $981 and has fallen 91.0% since, to $88 in 2025.
Across 150 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$311
- Novartis$297
- Johnson & Johnson$264
- Dermavant Sciences, Inc.$246
- Pfizer$243
- plus $915 from 17 others
Across 4 payments — averaging $3811.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$9K
- Journey Medical Corporation$7K
What the payments were for
- Food & beverage$3,26797%
- Education$1163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $1,108 |
| Lilly USA, LLC | 15 | $311 |
| Novartis | 14 | $297 |
| Johnson & Johnson | 17 | $264 |
| Dermavant Sciences, Inc. | 12 | $246 |
| Pfizer | 14 | $243 |
| Arcutis Biotherapeutics, Inc. | 12 | $208 |
| Amgen | 6 | $142 |
| Sun Pharmaceutical Industries Inc. | 4 | $98 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| E.r. Squibb & Sons, L.L.C. | 1 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Mayne Pharma Commercial LLC | 2 | $47 |
| Sanofi | 2 | $42 |
| Botanix SB Inc | 2 | $42 |
| Galderma Laboratories, L.p. | 2 | $39 |
| Nabriva Therapeutics, PLC | 1 | $25 |
| Incyte Corporation | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| LEO Pharma Inc. | 1 | $21 |
| EPI Health, LLC | 1 | $18 |
| UCB, Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,383 in reported general payments places this provider in the 55th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 315 | $625,214 |
| SkyriziRisankizumab-Rzaa | 23 | $442,366 |
| JubliaEfinaconazole | 296 | $386,247 |
| Dupixent PenDupilumab | 99 | $354,727 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $241,807 |
| ZoryveRoflumilast | 276 | $229,178 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 22 | $194,171 |
| Humira(Cf) PenAdalimumab | 13 | $168,467 |
| Dupixent SyringeDupilumab | 39 | $138,927 |
| Tacrolimus | 500 | $132,318 |
| VtamaTapinarof | 80 | $107,918 |
| Fluocinonide | 981 | $88,548 |
| Tretinoin | 781 | $69,034 |
| Clobetasol Propionate | 725 | $65,248 |
| OtezlaApremilast | 12 | $55,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $23 | $625,214315 claims |
| AbbVieSkyrizi | $1,108 | $442,36623 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $208 | $229,178276 claims |
| Dermavant Sciences, Inc.Vtama | $246 | $107,91880 claims |
| AmgenOtezla | $142 | $55,06812 claims |
| LEO Pharma Inc.Finacea | $21 | $14,09534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,151 dermatology providers in New York.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.